Author:
Milne Kate,Sturrock Beattie,Chevassut Timothy
Abstract
Abstract
Purpose of Review
Chronic lymphocytic leukaemia is now recognised as a heterogenous disease with a variety of clinical outcomes. Here we summarise the way it is currently stratified according to genetic risk and patient characteristics and the treatment approaches used for these different subgroups.
Recent Findings
Certain patients appear to sustain MRD negativity after combination chemoimmunotherapy, leading to the suggestion that their CLL may be cured. However, 17p-deleted, p53-mutated or IGHV-UM subgroups are generally resistant to FCR, and much better responses are seen with ibrutinib and venetoclax, frequently inducing MRD negativity that hopefully will be translated into durable remissions.
Summary
Small molecule inhibitors have already revolutionised CLL treatment. Going forward, we anticipate their use in the majority of patients, early after diagnosis and with curative intent.
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. Chronic lymphocytic leukemia - Cancer Stat Facts [Internet]. [cited 2019 Nov 17]. Available from: https://seer.cancer.gov/statfacts/html/clyl.html.
2. Chronic lymphocytic leukaemia (CLL) statistics | Cancer Research UK [Internet]. [cited 2019 Nov 17]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll#heading-Zero.
3. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511–7.
4. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.
5. Rai KR, Kipps TJ, Kay NE, Van Dyke D. NIH Public Access. 2011;203(2):134–40.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献